This comment to the SHARP Study discusses the possibility that liver transaminase alone may not represent optimal method to estimate liver function in CKD patients assuming statins.
Liver transaminase levels alone could not be the optimal method to estimate hepatic safety after statin administration in patients with chronic kidney disease.
TISEO, Ruana;DE GIORGI, Alfredo;PALA, Marco;MANFREDINI, Roberto
2011
Abstract
This comment to the SHARP Study discusses the possibility that liver transaminase alone may not represent optimal method to estimate liver function in CKD patients assuming statins.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
